This observation is important because numerous, next-generation agonists are being tested and rapidly advanced in the clinic,” said Dr. Vonderheide. In a new perspective piece published in Cancer Cell, he writes that the “immuno revolution” is upon us. Read more . . .
Robert Vonderheide, MD, director of the Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvannia, said CD40 agents could be the spark needed to light the fire in the immune systems of patients who do not respond to immunotherapies. “Activation of the CD40 molecule on dendritic cells holds a key to initiating a T-cell response to tumors.